Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited has successfully completed the exercise of preferred investment options, generating gross proceeds of approximately $3.3 million. The transaction, which closed on July 10, 2026, involved the issuance of 548,000 ordinary shares at a reduced exercise price of $6.00 per share. H.C. Wainwright & Co. served as the exclusive placement agent for this offering, which is expected to bolster the company's financial position as it continues to develop its innovative biotechnology solutions.

Founded with a focus on immune response detection and T cell immune profiling, Virax Biolabs is at the forefront of biotechnology aimed at addressing viral and immune-mediated diseases. The company's principal programs include ViraxImmune™, a T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a portfolio of research-use-only immune reagents. The recent fundraising effort will provide Virax with essential working capital to support ongoing research and development, particularly in the area of post-acute infection syndromes, including Long COVID.

The strategic rationale behind this fundraising is clear, as Virax seeks to expand its capabilities in a rapidly evolving sector. The biotechnology industry has seen significant growth in recent years, driven by an increasing demand for advanced diagnostic tools and therapeutics, particularly in the wake of the COVID-19 pandemic. By reducing the exercise price of the preferred investment options from the original $10.00 to $6.00, Virax has made it more attractive for investors to participate, thereby enhancing its liquidity and enabling it to pursue its ambitious development goals.

The issuance of new unregistered Series A and Series B Preferred Investment Options further illustrates Virax's proactive approach to capitalizing on market opportunities. These new warrants, which allow for the purchase of an additional 1,096,000 ordinary shares, will provide the company with additional flexibility in financing its operations and potential future growth initiatives. The strategic timing of this fundraising aligns with the company's broader objectives of increasing its market presence and advancing its product pipeline.

Looking ahead, the successful completion of this fundraising round may have broader implications for the biotechnology sector. As companies like Virax Biolabs continue to innovate and secure funding, investors may become increasingly optimistic about the potential for advancements in diagnostics and therapeutics. This trend could lead to heightened interest in biotech investments, particularly those focused on addressing unmet medical needs in the wake of the pandemic. Overall, Virax's recent capital raise positions it well to navigate the competitive landscape and capitalize on emerging opportunities in the biotechnology space.